ANI Pharmaceuticals (NASDAQ:ANIP) Director Patrick Walsh Sells 3,973 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 3,973 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $80.75, for a total value of $320,819.75. Following the transaction, the director owned 48,432 shares of the company’s stock, valued at $3,910,884. The trade was a 7.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $80.88 on Thursday. The stock has a market cap of $1.81 billion, a PE ratio of 20.48 and a beta of 0.46. The stock has a 50-day moving average of $77.19 and a 200-day moving average of $80.60. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current year.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat first-quarter expectations, reporting $2.05 EPS versus the $1.28 consensus and revenue of $237.46 million versus $207.63 million expected. The company also raised/affirmed FY2026 guidance at $9.19-$9.69 EPS, supporting the case for continued fundamental strength.
• Positive Sentiment: Analyst sentiment remains constructive, with upgrades from Zacks Research and Wall Street Zen and a consensus “Moderate Buy” rating plus a $107.33 target price, which can help support investor confidence.
• Neutral Sentiment: ANI Pharmaceuticals published an updated investor presentation highlighting non-GAAP metrics, which may be viewed as a routine disclosure but does not appear to materially change the near-term outlook on its own. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
• Negative Sentiment: Several insiders sold shares, including CEO Nikhil Lalwani, who sold 55,000 shares, along with sales by directors and executives Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland. Heavy insider selling can raise caution among investors, even if some transactions were pre-planned.
• Negative Sentiment: A separate report said Global Alpha dumped 229,000 ANIP shares worth about $17.9 million, adding to concerns that some large holders may be trimming exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Wall Street Analyst Weigh In

ANIP has been the topic of a number of research reports. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently bought and sold shares of the company. Sei Investments Co. lifted its position in shares of ANI Pharmaceuticals by 36.8% in the first quarter. Sei Investments Co. now owns 57,168 shares of the specialty pharmaceutical company’s stock worth $4,395,000 after purchasing an additional 15,367 shares in the last quarter. Walleye Capital LLC increased its stake in ANI Pharmaceuticals by 56.1% in the 1st quarter. Walleye Capital LLC now owns 183,075 shares of the specialty pharmaceutical company’s stock valued at $14,078,000 after buying an additional 65,768 shares during the last quarter. Globeflex Capital L P lifted its position in ANI Pharmaceuticals by 52.0% during the 1st quarter. Globeflex Capital L P now owns 84,145 shares of the specialty pharmaceutical company’s stock worth $6,471,000 after buying an additional 28,784 shares in the last quarter. Cetera Investment Advisers acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $373,000. Finally, First Trust Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 12.8% in the 1st quarter. First Trust Advisors LP now owns 99,747 shares of the specialty pharmaceutical company’s stock valued at $7,671,000 after acquiring an additional 11,346 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.